SELECTED BIOMARKERS IN SEPSIS: IL-6, sTREM-1 AND NEUTROPHIL CD64 - A LITERATURE REVIEW
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5632Keywords:
Sepsis, Biomarkers, Interleukin-6, sTREM-1, Neutrophil CD64Abstract
Background: Sepsis is a life-threatening condition characterised by organ dysfunction caused by a dysregulated host response to infection and remains a major cause of morbidity and mortality worldwide. Early recognition is clinically challenging because initial symptoms are non-specific and commonly used inflammatory markers have limited diagnostic performance. Consequently, there is ongoing interest in biomarkers that enable faster and more accurate identification of sepsis.
Aim: To discuss selected sepsis biomarkers: interleukin-6 (IL-6), soluble TREM-1 (sTREM-1), and neutrophil CD64 expression, with particular emphasis on biological mechanisms, clinical utility, and diagnostic limitations.
Materials and methods: A narrative review of the literature was undertaken. Publications from 2016 to 2025 indexed in PubMed/MEDLINE, Scopus, and Google Scholar were analysed, including clinical studies, reviews, and meta-analyses. Evidence was assessed with respect to biological mechanisms, diagnostic and prognostic performance, and limitations of the biomarkers.
Results: Neutrophil CD64 expression shows high specificity for bacterial infection and sepsis; however, routine use is constrained by limited assay standardisation and the absence of validated cut-off values. IL-6 rises very early and has prognostic value, correlating with the severity of organ dysfunction and mortality risk, but it has low specificity. sTREM-1 reflects activation of the TREM-1 axis and the intensity of the inflammatory response; however, its ability to distinguish sepsis from non-infectious SIRS is limited.
Conclusions: None of the reviewed biomarkers should be used as a stand-alone diagnostic test. The greatest clinical value is likely to be achieved with a multiparametric approach that combines clinical assessment and organ dysfunction scores with biomarkers representing different stages of the immune response. This strategy may improve early recognition, risk stratification, and monitoring of sepsis.
References
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J. D., Coopersmith, C. M., Hotchkiss, R. S., Levy, M. M., Marshall, J. C., Martin, G. S., Opal, S. M., Rubenfeld, G. D., van der Poll, T., Vincent, J. L., & Angus, D. C. (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA, 315(8), 801–810. https://doi.org/10.1001/jama.2016.0287
Piękoś, D., Stachowicz, A., Sobczyk, G., & Ozga, D. (2018). Practical possibilities in using qSOFA scale by emergency medical teams. Journal of Education, Health and Sport, 8(8), 735–742.
Ahmad, A., Imran, M., & Ahsan, H. (2023). Biomarkers as biomedical bioindicators: Approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics, 15(6), 1630. https://doi.org/10.3390/pharmaceutics15061630
La Via, L., Sangiorgio, G., Stefani, S., Marino, A., Nunnari, G., Cocuzza, S., La Mantia, I., Cacopardo, B., Stracquadanio, S., Spampinato, S., et al. (2024). The global burden of sepsis and septic shock. Epidemiologia, 5, 456–478. https://doi.org/10.3390/epidemiologia5030032
Gray, A. P., Chung, E., Hsu, R. L., et al. (2025). Global, regional, and national sepsis incidence and mortality, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet Global Health. https://doi.org/10.1016/S2214-109X(25)00356-0
Fleischmann-Struzek, C., Mellhammar, L., Rose, N., Cassini, A., Rudd, K. E., Schlattmann, P., Allegranzi, B., & Reinhart, K. (2020). Incidence and mortality of hospital- and ICU-treated sepsis: Results from an updated and expanded systematic review and meta-analysis. Intensive Care Medicine, 46(8), 1552–1562. https://doi.org/10.1007/s00134-020-06151-x
Tan, M., Lu, Y., Jiang, H., & Zhang, L. (2019). The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. Journal of Cellular Biochemistry, 120(4), 5852–5859. https://doi.org/10.1002/jcb.27870
Nargis, W., Ibrahim, M., & Ahamed, B. U. (2014). Procalcitonin versus C-reactive protein: Usefulness as biomarker of sepsis in ICU patients. International Journal of Critical Illness and Injury Science, 4(3), 195–199. https://doi.org/10.4103/2229-5151.141356
Daud, M., Khan, M. B., Qudrat, Q. U., Ullah, I., Khan, S., Khan, M. Z., Yousuf, I., & Ahmad, F. (2024). Role of C-reactive protein and procalcitonin in early diagnostic accuracy and their prognostic significance in sepsis. Cureus, 16(9), e70358. https://doi.org/10.7759/cureus.70358
Zhang, H., Wang, X., Zhang, Q., et al. (2017). Comparison of procalcitonin and high-sensitivity C-reactive protein for the diagnosis of sepsis and septic shock in the oldest old patients. BMC Geriatrics, 17, 173. https://doi.org/10.1186/s12877-017-0566-5
Patnaik, R., Azim, A., & Agarwal, V. (2020). Neutrophil CD64: A diagnostic and prognostic marker of sepsis in adult critically ill patients—A brief review. Indian Journal of Critical Care Medicine, 24, 124–131. https://doi.org/10.5005/jp-journals-10071-23558
Cong, S., Ma, T., Di, X., et al. (2021). Diagnostic value of neutrophil CD64, procalcitonin, and interleukin-6 in sepsis: A meta-analysis. BMC Infectious Diseases, 21, 384. https://doi.org/10.1186/s12879-021-06064-0
Dal Ponte, S. T., Alegretti, A. P., Pilger, D. A., Rezende, G. P., Andrioli, G., Ludwig, H. C., Diogo, L., Goldani, L. Z., Loreto, M., Machado, P. S., & Seligman, R. (2018). Diagnostic accuracy of CD64 for sepsis in the emergency department. Journal of Global Infectious Diseases, 10(2), 42–46. https://doi.org/10.4103/jgid.jgid_130_16
Mansur Aliyu, Zohora, F. T., Anka, A. U., Ali, K., Maleknia, S., Saffarioun, M., & Azizi, G. (2022). Interleukin-6 cytokine: An overview of immune regulation, immune dysregulation, and therapeutic approach. International Immunopharmacology, 111, 109130. https://doi.org/10.1016/j.intimp.2022.109130
Gulhar, R., Ashraf, M. A., & Jialal, I. (2025). Physiology, acute phase reactants. In StatPearls. StatPearls Publishing.
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspectives in Biology, 6(10), a016295. https://doi.org/10.1101/cshperspect.a016295
Candelli, M., Sacco Fernandez, M., Rozzi, G., Sodero, G., Piccioni, A., Pignataro, G., Rigante, D., & Franceschi, F. (2025). The interleukin network in sepsis: From cytokine storm to clinical applications. Diagnostics, 15, 2927. https://doi.org/10.3390/diagnostics15222927
Ameen, S. S., Hegde, S., Parida, A., Kateel, R., & V, M. (2025). Interleukin-6 as a biomarker of sepsis and its clinical utility in predicting mortality: A prospective observational study. Journal of Infection in Developing Countries, 19(10), 1470–1478. https://doi.org/10.3855/jidc.20800
Yu, B., Chen, M., Zhang, Y., Cao, Y., Yang, J., Wei, B., & Wang, J. (2022). Diagnostic and prognostic value of interleukin-6 in emergency department sepsis patients. Infection and Drug Resistance, 15, 5557–5566. https://doi.org/10.2147/IDR.S384351
Jawa, R. S., Anillo, S., Huntoon, K., Baumann, H., & Kulaylat, M. (2010). Interleukin-6 in surgery, trauma, and critical care: Part II: Clinical implications. Journal of Intensive Care Medicine, 26(2), 73–87. https://doi.org/10.1177/0885066610384188
Hirano, T. (2021). IL-6 in inflammation, autoimmunity and cancer. International Immunology, 33(3), 127–148. https://doi.org/10.1093/intimm/dxaa078
Siskind, S., Brenner, M., & Wang, P. (2022). TREM-1 modulation strategies for sepsis. Frontiers in Immunology, 13, 907387. https://doi.org/10.3389/fimmu.2022.907387
Zhang, C., Kan, X., Zhang, B., et al. (2022). The role of triggering receptor expressed on myeloid cells-1 (TREM-1) in central nervous system diseases. Molecular Brain, 15, 84. https://doi.org/10.1186/s13041-022-00969-w
Jedynak, M., Siemiątkowski, A., Milewski, R., Mroczko, B., & Szmitkowski, M. (2019). Diagnostic effectiveness of soluble triggering receptor expressed on myeloid cells-1 in sepsis, severe sepsis and septic shock. Archives of Medical Science, 15(3), 713–721. https://doi.org/10.5114/aoms.2018.73090
He, R. R., Yue, G. L., Dong, M. L., Wang, J. Q., & Cheng, C. (2024). Sepsis biomarkers: Advancements and clinical applications—A narrative review. International Journal of Molecular Sciences, 25(16), 9010. https://doi.org/10.3390/ijms25169010
Chen, L., Zhang, X., & Shi, P. (2025). Recent advances in biomarkers for detection and diagnosis of sepsis and organ dysfunction: A comprehensive review. European Journal of Medical Research, 30, 1081. https://doi.org/10.1186/s40001-025-03324-6
Leszcz, M., Więckowska-Deroń, M., Nitka, K., Białek, J., Ćwik-Błotnicka, D., & Borczyk, J. (2023). CRP—A valuable source of information or just a laboratory test? Journal of Education, Health and Sport, 45(1), 366–377. https://doi.org/10.12775/JEHS.2023.45.01.026
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Aleksander Midera, Kinga Popielarska, Klaudia Elżbieta Niwińska, Natalia Maria Leśniak, Anna Maria Zakrzewska, Julia Aleksandra Leśniak, Michał Borowski, Julia Agnieszka Michalak, Monika Augustyn
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
